4.37
price down icon1.35%   -0.06
after-market Handel nachbörslich: 4.37
loading
Schlusskurs vom Vortag:
$4.43
Offen:
$4.44
24-Stunden-Volumen:
26,869
Relative Volume:
0.56
Marktkapitalisierung:
$186.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.97M
KGV:
-7.0484
EPS:
-0.62
Netto-Cashflow:
$-17.74M
1W Leistung:
+1.16%
1M Leistung:
+0.23%
6M Leistung:
+45.67%
1J Leistung:
+72.05%
1-Tages-Spanne:
Value
$4.3501
$4.44
1-Wochen-Bereich:
Value
$4.05
$4.48
52-Wochen-Spanne:
Value
$2.12
$4.95

Diamedica Therapeutics Inc Stock (DMAC) Company Profile

Name
Firmenname
Diamedica Therapeutics Inc
Name
Telefon
(763) 496-5454
Name
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Name
Mitarbeiter
19
Name
Twitter
@diamedica
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
DMAC's Discussions on Twitter

Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-04-09 Eingeleitet Oppenheimer Outperform
2021-02-17 Eingeleitet ROTH Capital Buy
2020-10-30 Eingeleitet Guggenheim Buy
2020-07-08 Eingeleitet Maxim Group Buy
2019-04-30 Eingeleitet Dougherty & Company Buy
2019-03-05 Eingeleitet Lake Street Buy
Alle ansehen

Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten

pulisher
Oct 27, 2024

Blue Trust Inc. Makes New Investment in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World

Oct 27, 2024
pulisher
Oct 15, 2024

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Large Growth in Short Interest - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

Best Momentum Stocks to Buy for October 14th - Yahoo Canada Finance

Oct 14, 2024
pulisher
Oct 13, 2024

Head to Head Contrast: DiaMedica Therapeutics (NASDAQ:DMAC) versus Provectus Biopharmaceuticals (OTCMKTS:PVCT) - Defense World

Oct 13, 2024
pulisher
Oct 10, 2024

DiaMedica shares maintain Buy rating from H.C. Wainwright - Investing.com

Oct 10, 2024
pulisher
Oct 10, 2024

DiaMedica shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa

Oct 10, 2024
pulisher
Oct 10, 2024

DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial - Yahoo Finance

Oct 10, 2024
pulisher
Oct 09, 2024

DiaMedica advances preeclampsia treatment with trial approval By Investing.com - Investing.com South Africa

Oct 09, 2024
pulisher
Oct 09, 2024

DiaMedica advances preeclampsia treatment with trial approval - Investing.com India

Oct 09, 2024
pulisher
Oct 09, 2024

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire

Oct 09, 2024
pulisher
Oct 09, 2024

Research Analysts Offer Predictions for DiaMedica Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:DMAC) - MarketBeat

Oct 09, 2024
pulisher
Oct 07, 2024

H.C. Wainwright initiates DiaMedica shares with Buy rating on stroke treatment By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

H.C. Wainwright initiates DiaMedica shares with Buy rating on stroke treatment - Investing.com India

Oct 07, 2024
pulisher
Oct 07, 2024

DiaMedica Therapeutics (NASDAQ:DMAC) Coverage Initiated by Analysts at HC Wainwright - MarketBeat

Oct 07, 2024
pulisher
Oct 04, 2024

DiaMedica: Readying For REDUX Readout - RTTNews

Oct 04, 2024
pulisher
Oct 01, 2024

Magnolia Capital Advisors LLC Buys New Stake in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World

Oct 01, 2024
pulisher
Sep 24, 2024

Point72 DIFC Ltd Acquires Shares of 2,848 Mettler-Toledo International Inc. (NYSE:MTD) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Commonwealth Equity Services LLC Invests $303,000 in Diebold Nixdorf, Incorporated (NYSE:DBD) - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

US FDA Closes Out Problem Applications One Federal Register Notice At A Time - Pink Sheet

Sep 23, 2024
pulisher
Sep 23, 2024

Ameritas Investment Partners Inc. Has $1.82 Million Stake in Dolby Laboratories, Inc. (NYSE:DLB) - Defense World

Sep 23, 2024
pulisher
Sep 22, 2024

Domino’s Pizza, Inc. (NYSE:DPZ) Position Lowered by Epoch Investment Partners Inc. - Defense World

Sep 22, 2024
pulisher
Sep 21, 2024

Victory Capital Management Inc. Sells 10,924 Shares of Dolby Laboratories, Inc. (NYSE:DLB) - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Dolby Laboratories, Inc. (NYSE:DLB) Shares Sold by Federated Hermes Inc. - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

Deftones’ Album Rises To A New Peak–Nearly 20 Years After Its Release - Forbes

Sep 20, 2024
pulisher
Sep 19, 2024

Deutsche Telekom downgraded to Neutral from Outperform at Oddo BHF - TipRanks

Sep 19, 2024
pulisher
Sep 12, 2024

Insiders See US$9.05m Investment In DiaMedica Therapeutics Jump Last Week - Simply Wall St

Sep 12, 2024
pulisher
Sep 10, 2024

DiaMedica Therapeutics (NASDAQ:DMAC) Shares Up 2.7% - Defense World

Sep 10, 2024
pulisher
Sep 10, 2024

DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 2.7% - MarketBeat

Sep 10, 2024
pulisher
Sep 10, 2024

DMAC stock touches 52-week high at $4.11 amid bullish trend - Investing.com

Sep 10, 2024
pulisher
Sep 04, 2024

DiaMedica Therapeutics Upcoming Conference Participation - Business Wire

Sep 04, 2024
pulisher
Sep 03, 2024

Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Sep 03, 2024
pulisher
Aug 22, 2024

DMAC stock touches 52-week high at $3.85 amid robust gains - Investing.com

Aug 22, 2024
pulisher
Aug 19, 2024

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Shares Purchased by Vanguard Group Inc. - Defense World

Aug 19, 2024
pulisher
Aug 19, 2024

Vanguard Group Inc. Acquires 211,351 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - MarketBeat

Aug 19, 2024
pulisher
Aug 18, 2024

Oppenheimer Reiterates “Outperform” Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - Defense World

Aug 18, 2024
pulisher
Aug 16, 2024

DiaMedica Therapeutics' (DMAC) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat

Aug 16, 2024
pulisher
Aug 16, 2024

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update - MarketBeat

Aug 16, 2024
pulisher
Aug 16, 2024

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 17.0% in July - Defense World

Aug 16, 2024
pulisher
Aug 12, 2024

Earnings call: DiaMedica Therapeutics highlights solid progress in Q2 - Investing.com

Aug 12, 2024
pulisher
Aug 12, 2024

Earnings call: DiaMedica Therapeutics highlights solid progress in Q2 By Investing.com - Investing.com Canada

Aug 12, 2024
pulisher
Aug 12, 2024

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2024 Earnings Call Transcript - Insider Monkey

Aug 12, 2024
pulisher
Aug 11, 2024

DiaMedica Therapeutics Inc. (DMAC) Q2 2024 Earnings Call Transcript - Seeking Alpha

Aug 11, 2024
pulisher
Aug 10, 2024

DiaMedica Therapeutics (NASDAQ:DMAC) Releases Earnings Results - MarketBeat

Aug 10, 2024
pulisher
Aug 07, 2024

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results - Business Wire

Aug 07, 2024
pulisher
Aug 05, 2024

DiaMedica Therapeutics (DMAC) to Release Earnings on Wednesday - Defense World

Aug 05, 2024
pulisher
Aug 02, 2024

DiaMedica Therapeutics (DMAC) Scheduled to Post Earnings on Wednesday - MarketBeat

Aug 02, 2024
pulisher
Aug 01, 2024

Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year? - Yahoo Finance

Aug 01, 2024
pulisher
Aug 01, 2024

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024 - Business Wire

Aug 01, 2024
pulisher
Jul 30, 2024

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 10.8% in July - MarketBeat

Jul 30, 2024
pulisher
Jul 30, 2024

Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 10.8% - Defense World

Jul 30, 2024
pulisher
Jul 16, 2024

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 22.1% in June - MarketBeat

Jul 16, 2024

Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Diamedica Therapeutics Inc-Aktie (DMAC) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
STAHLBERG JAN
10% Owner
Jun 28 '24
Buy
2.50
1,200,000
3,000,000
5,221,608
Wambeke David J.
Chief Business Officer
Nov 16 '23
Buy
2.46
20,000
49,200
527,114
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):